$AMPE Headlines 6 stocks to watch 2:56 p.m. June 18,

New Post Public Reply Private Reply Replies (0) Message Board

Jan 26, 2015 at 12:40 PM

$AMPE Headlines

6 stocks to watch 2:56 p.m. June 18, 2014 - The Trading Deck
Friday’s biggest gaining and declining stocks 3:26 p.m. July 13, 2012 - MarketWatch
Stocks to watch Friday: Lexmark, New York & Co. 5:47 a.m. July 13, 2012 - MarketWatch
Monday’s biggest gaining and declining stocks 3:50 p.m. June 11, 2012 - MarketWatch
Ampio: Optina has potential for diabetic treatment 11:46 a.m. June 11, 2012 - MarketWatch.com
Ampio shares add 27% after positive trial results 6:26 a.m. June 11, 2012 - Greg Morcroft
Tuesday’s biggest gaining and declining stocks 12:50 p.m. March 20, 2012 - Kate Gibson
Ampio rallies on eye-drug study 11:52 a.m. March 19, 2012 - Val Brickates Kennedy
Ampio tumbles on stock placement 2:50 p.m. Dec. 21, 2011 - Val Brickates Kennedy
Monday’s biggest gaining and declining stocks 4:38 p.m. Dec. 19, 2011 - Greg Morcroft
Ampio Pharmaceuticals tumbles on drug concerns 2:57 p.m. Dec. 15, 2011 - Val Brickates Kennedy

Interesting AMPE Put And Call Options For March 20th 53 min ago - TheStreet.com
Ampio Pharmaceuticals (AMPE) in Focus: Stock Surges 14.1% - Tale of the Tape 9:39 a.m. Jan. 15, 2015 - Zacks.com
Ampio Pharma up after Vyrix presentation 3:45 p.m. Jan. 14, 2015 - Seeking Alpha
Ampio off premarket on expansion of data analysis in STRUT trial 9:05 a.m. Nov. 12, 2014 - Seeking Alpha
10-Q: AMPIO PHARMACEUTICALS, INC. 8:33 a.m. Nov. 7, 2014 - Edgar Online - (EDG = 10Q, 10K)
Will Ampio (AMPE) Continue to Surge Higher? - Tale of the Tape 9:01 a.m. Oct. 20, 2014 - Zacks.com
Ironwood/Actavis Move Linzess into Phase II Study for OIC - Analyst Blog 3:40 p.m. Oct. 17, 2014 - Zacks.com
ChemoCentryx, Inc. (CCXI) in Focus: Stock Rises 9.6% - Tale of the Tape 8:32 a.m. Oct. 17, 2014 - Zacks.com
Tetraphase (TTPH) Crumbles: Stock Tanks by 15% - Tale of the Tape 7:55 a.m. Oct. 17, 2014 - Zacks.com
Ohr Pharmaceutical's OHR-102 to Enter Phase III in 1H15 - Analyst Blog 6:00 p.m. Oct. 16, 2014 - Zacks.com
Corcept Therapeutics (CORT) Jumps: Stock Rises 6.4% - Tale of the Tape 8:32 a.m. Oct. 15, 2014 - Zacks.com
ARIAD's Iclusig Gains Positive Recommendation from PRAC - Analyst Blog 4:05 p.m. Oct. 14, 2014 - Zacks.com
Esperion Therapeutics Slumps: ESPR Falls 6.3% in Session - Tale of the Tape 7:48 a.m. Oct. 13, 2014 - Zacks.com
Genocea Up on Positive GEN-003 Data for Genital Herpes - Analyst Blog 1:57 p.m. Oct. 9, 2014 - Zacks.com
Xenon Pharma on deck for IPO 10:57 a.m. Oct. 7, 2014 - Seeking Alpha
Karyopharm Therapeutics, Inc. (KPTI) Surges: Stock Adds 10.5% - Tale of the Tape 8:11 a.m. Sept. 29, 2014 - Zacks.com
Another Mixed Stock Market Day but Indexes May Go Higher Friday 4:24 p.m. Sept. 11, 2014 - TheStreet.com
U.S. Stocks Stage Unimpressive Rebound as Apple Leads the Way 4:42 p.m. Sept. 10, 2014 - TheStreet.com
Simple Math Shows Ampio Knee Arthritis Drug is No Better Than Saline 11:04 a.m. Sept. 3, 2014 - TheStreet.com
Ampio Pharmaceuticals (AMPE): Today's Weak On High Volume Stock 9:05 a.m. Sept. 3, 2014 - TheStreet.com

Luoxis Establishes Initial European Distribution Network for RedoxSYS™ Diagnostic System 8:00 a.m. Jan. 22, 2015 - PR Newswire - PRF
Vyrix Pharmaceuticals to Present at Biotech Showcase™ 2015 7:57 a.m. Jan. 8, 2015 - PR Newswire - PRF
Luoxis to Present at Biotech Showcase 2015 8:00 a.m. Jan. 6, 2015 - PR Newswire - PRF
Ampio Pharmaceuticals to present at the Oppenheimer Annual Healthcare Conference on December 11th, 2014 8:00 a.m. Dec. 4, 2014 - PR Newswire - PRF
Ampio Announces Results of the Open Label Portion of the Multiple Intra-articular Injections (STRUT) Study of Ampion™ in Patients with Osteoarthritis of the Knee at Week Twenty of the Trial 8:00 a.m. Dec. 1, 2014 - PR Newswire - PRF
Luoxis Announces Presentation of Multiple Studies Validating RedoxSYS as a Rapid and Non-invasive Means of Assessing Oxidative Stress 8:00 a.m. Nov. 24, 2014 - PR Newswire - PRF
Ampio updates status of clinical trials and manufacturing facility 8:00 a.m. Nov. 12, 2014 - PR Newswire - PRF
Technical Report on Pharma Stocks - Auxilium Pharma, Perrigo, Endo Intl., Depomed, and Ampio Pharma 7:45 a.m. Oct. 24, 2014 - PR Newswire - PRF
Luoxis to Highlight RedoxSYS at Two Upcoming Scientific Conferences 7:00 a.m. Oct. 20, 2014 - PR Newswire - PRF
Ampio Announces Results of the Open Label Portion of the Multiple Intra-articular Injections (MI) Study of Ampion™ in Patients with Osteoarthritis of the Knee at Week Twelve of the Trial 3:02 p.m. Oct. 16, 2014 - PR Newswire - PRF
Ampio Pharmaceuticals Announces Webcast for Annual Shareholder Meeting 1:00 p.m. Sept. 15, 2014 - PR Newswire - PRF
Health Care Sector Stocks Technical Review - Ampio Pharma, InterMune, Biogen Idec, Hologic, and CareFusion Corp. 7:40 a.m. Sept. 15, 2014 - PR Newswire - PRF
Robbins Arroyo LLP is Investigating the Officers and Directors of Ampio Pharmaceuticals, Inc. (AMPE) on Behalf of Shareholders 1:43 p.m. Aug. 28, 2014 - GlobeNewswire
Letter to the Ampio Shareholders in Regard to the STEP Study and Ampio's plans for the Ampion™ BLA 6:56 a.m. Aug. 25, 2014 - PR Newswire - PRF
Ampio reports that due to temperature deviations below product specifications during shipments to the Ampion™ STEP Study clinical sites, release of data will be delayed 6:56 a.m. Aug. 21, 2014 - PR Newswire - PRF
Luoxis Announces Presentation of Positive Clinical Findings from Five-Year Clinical Study of Traumatic Brain Injury and Oxidation-Reduction Potential at 2014 American Academy of Surgical Trauma Meeting 6:56 a.m. Aug. 19, 2014 - PR Newswire - PRF
Ampio Announces Very Positive Results of the Open Label Portion of the Multiple Intra-articular Injections Study of Ampion™ in Patients with Osteoarthritis of the Knee at Week Six of the Trial 7:00 a.m. Aug. 18, 2014 - PR Newswire - PRF
Luoxis Broadens Global Research Network for RedoxSYS™ oxidation-reduction potential (ORP) diagnostic system; Announces 17 Studies Currently Underway and Additional 30 Studies Set to Begin in 2014 7:00 a.m. Aug. 11, 2014 - PR Newswire - PRF
Ampio announces positive results on the open label portion of the Multiple injection Study of Ampion™ in patients with osteoarthritis of the knee. 7:00 a.m. Aug. 5, 2014 - PR Newswire - PRF
Ophthalmic Drugs Market Forecast 2014-2024: Prospects for Leading Companies 10:55 a.m. Aug. 4, 2014 - PR Newswire - PRF

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Labcorp Lifts 2026 Guidance Amid Strong Q3 Performance

Labcorp's Q3 Numbers Speak Loud and Clear Another quarter, another robust set of numbers for Labcorp (NYSE:LH). The company is strutting into the spotlight with third-quarter 2026 results that have investors nodding in approval. Revenue surged to $3.81 billion, marking a 6.9% increase from the prior year's $3.56 billion. And get this: adjusted EPS jumped 14.5%, clocking...

SoftwareOne Triumphs in 2026 GitHub Partner Awards

SoftwareOne Nabs Prestigious GitHub Honor Outta nowhere, SoftwareOne's been lashed onto the center stage, bagging GitHub's Global Channel Sales Partner of the Year for 2026. This ain't just another shiny trophy on the shelf; it's a solid nod to their grit and strategy. Now, if good old GitHub says you're their top dog, you're obviously doing something right. Not bad for a...

AppLovin Faces Class Action: AI Growth Claims Under Fire

AppLovin's AI Jackpot: A Busted Flush? This year's been a rollercoaster at AppLovin Corporation, and not the fun kind. Let me tell ya, investors bought into a dream—a self-sustaining, profit-churning machine based on AI advertising models. Unfortunately, reality came around like a bad penny, and suddenly, their 'virtuous cycle' feels more like a busted flush....

HERVolution's HERV-K Antigens: A Cancer Breakthrough?

Digging into HERVolution's Game-Changing Data Picture HERVolution in the spotlight, rolling out data that could shake up our approach to cancer immunotherapy. The big headline? HERV-K antigens might just be the whistle-blower we've been looking for to get the immune system off the bench and onto the field. How's that for a kick in the conventional wisdom of cancer...

QFIN Faces Lawsuit Over Broken Promises and Revenue Plunge

Unmasking the Hype: QFIN's Pledge and Performance Investors, gather 'round because QFIN's latest uproar ain't pretty. The folks over at Qfin Holdings have found themselves in hot water, facing a class action lawsuit for allegedly pulling the wool over investors' eyes. Between March and August 2026, they promised a rock-solid ship braving China’s regulatory storm. Turns...

Lynk Pharmaceuticals' Zemprocitinib Shines in Phase III RA Trial

A Deep Dive into Lynk Pharmaceuticals' Latest Revelation Lynk Pharmaceuticals just dropped a bombshell with their latest Phase III trial results for zemprocitinib. This selective JAK1 inhibitor seems to be bringing some serious game in the fight against moderate-to-severe rheumatoid arthritis (RA), especially for folks who haven't had much luck with biologics. The drug...

Faith on Trial: La Luz del Mundo Faces Court Ruling

A Legal Battle Over Religious Freedom When folks start talking about religion intertwining with law, things get real tricky, real quick. The La Luz del Mundo church is knee-deep in such a legal tussle. On October 28, 2026, the United States District Court for the Southern District of New York gave a nod to the prosecution, denying the church's pretrial motions. What we've...

Corgi Insurance Eyes $100B Auto Market with New Launch

Leaping Into a Booming Market Well, it looks like someone lit a fire under Corgi Insurance, and they're ready to chase bigger bones. They’ve just rolled out a product called Corgi Business Auto, signaling quite a bold move into the hefty, nearly $100 billion U.S. commercial auto insurance arena. Now, as an old hand at this game, my ears perk up whenever I see a player...

Pave and Levels.fyi Unite: Revolutionize Pay Decisions

Diving straight into the heart of it, here's a move in the business world that's all but marking its territory on the compensation landscape. Pave, already a big player in agentic compensation management, is shaking hands with Levels.fyi, a platform prized for its real-deal compensation data detailed down to the company, level, location, and skill. These folks are...

Honeywell Aerospace Posts Solid Q3, Raises Guidance

Honeywell Aerospace Surprises with Strong Third Quarter In a world where numbers are often as slippery as a greased pig, Honeywell Aerospace (NASDAQ:HONA) has managed to pin down a surprisingly robust third quarter. Let’s break it down: they’ve claimed sales of a cool $4.6 billion, reflecting a 2% bump both in reported and organic revenue from the previous year, and...